This article compares the pharmacokinetics, toxicity, and clinical efficacy of high-dose intravenous, low-dose intravenous, and intermediate-dose subcutaneous recombinant interleukin-2 (rIL-2) regimens in patients with measurable metastatic renal cell carcinoma.
PATIENTS AND METHODS
This trial began as a two-arm randomized study comparing two… (More)
Figures and Tables
Sorry, we couldn't extract any figures or tables for this paper.